Quick Takeaways
- Invus Global Management, LLC filed SCHEDULE 13G for Tango Therapeutics, Inc. Common Stock, $0.001 par value per share (TNGX).
- Disclosed ownership: 5.3%.
- Date of event: 19 Sep 2025.
Quoteable Key Fact
"Invus Global Management, LLC disclosed 5.3% ownership in Tango Therapeutics, Inc. Common Stock, $0.001 par value per share (TNGX) on 19 Sep 2025."
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original Filing| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Invus Public Equities, L.P. | 4.6% | 5,082,716 | 5,082,716 | 0 | /s/ Raymond Debbane | Raymond Debbane, President of Invus Public Equities Advisors, LLC, its general partner | |
| Invus Public Equities Advisors, LLC | 4.6% | 5,082,716 | 5,082,716 | 0 | /s/ Raymond Debbane | Raymond Debbane, President | |
| Invus Global Management, LLC | 4.6% | 5,082,716 | 5,082,716 | 0 | /s/ Raymond Debbane | Raymond Debbane, President | |
| Siren, L.L.C. | 4.6% | 5,082,716 | 5,082,716 | 0 | /s/ Raymond Debbane | Raymond Debbane, President | |
| Avicenna Life Sci Master Fund LP | 0.7% | 800,472 | 800,472 | 0 | /s/ Raymond Debbane | Raymond Debbane, Chief Executive Officer of Avicenna Life Sci Master GP LLC, its general partner | |
| Avicenna Life Sci Master GP LLC | 0.7% | 800,472 | 800,472 | 0 | /s/ Raymond Debbane | Raymond Debbane, Chief Executive Officer | |
| Ulys, L.L.C. | 0.7% | 800,472 | 800,472 | 0 | /s/ Raymond Debbane | Raymond Debbane, President | |
| Raymond Debbane | 5.3% | 5,883,188 | 5,883,188 | 0 | /s/ Raymond Debbane | Raymond Debbane |